| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Selenium NanoParticles| Category | Role in cancer | | -------------------------------- | ----------------------------------------------------------------------------------------------- | | Sodium Selenium (selenite) | Direct cytotoxic redox poison | | Selenium (organic / nutritional) | **Redox buffer & immune modulator** (generally *anti-therapy* when oxidative stress is desired) | | SeNPs | Tunable redox-signaling anticancer platform |The introduction of borneol led to a significant reduction in the size of selenium nanoparticles (SeNPs), as documented in the study (Prabhakaret et al., 2013). In the chemical synthesis of selenium nanoparticles, a precursor such as sodium selenite (Na₂SeO₃) is dissolved in water to form a homogenous solution. A reducing agent, like ascorbic acid or sodium borohydride (NaBH₄), is then added to the solution. The reducing agent donates electrons to the selenium ions (SeO32−SeO32), reducing them to elemental selenium (Se0Se^0). This reduction process leads to the nucleation of selenium atoms, which subsequently grow into nanoparticles through controlled aggregation. Se NPs might be hepatoprotective. (chemoprotective) (radioprotective) (radiosensitizer)
Selenium nanoparticles (SeNPs) are a biocompatible, less-toxic,
and more controllable form of selenium compared to inorganic salts (like sodium selenite).
Major SeNPs hepatoprotective mechanisms
Mechanism Description Key markers affected
1. Antioxidant activity SeNPs boost antioxidant enzyme ↓ ROS, ↓ MDA, ↑ GSH, ↑ GPx
systems (GPx, SOD, CAT) and scavenge
ROS directly.
2. Anti-inflammatory effect Downregulate NF-κB, TNF-α, ↓ TNF-α, ↓ IL-1β, ↓ IL-6
IL-6, and COX-2 pathways.
3. Anti-apoptotic action Balance between Bcl-2/Bax and reduce ↑ Bcl-2, ↓ Bax, ↓ Caspase-3
caspase-3 activation in hepatocytes.
4. Metal/toxin chelation SeNPs can bind or transform toxic ↓ liver metal accumulation
metals (Cd²⁺, Hg²⁺, As³⁺)
into less harmful complexes.
5. Mitochondrial protection Maintain membrane potential, Preserved ΔΨm, ↑ ATP
prevent mitochondrial ROS burst,
and ATP loss.
6. Regeneration support Stimulate hepatocyte proliferation ↑ PCNA, improved histology
and repair via redox signaling
and selenoproteins.
Comparison: SeNPs vs. Sodium Selenite
Property SeNPs Sodium Selenite
Toxicity Low Moderate–high
Bioavailability Controlled, often slow- Rapid, less controllable
release
ROS balance Adaptive, mild antioxidant Can flip to pro-oxidant easily
Safety margin Wide Narrow
Hepatoprotection Strong, sustained Protective at low dose,
toxic at high dose
Form of SeNPs matter:1. Core composition / capping agent: SeNPs can be stabilized with polysaccharides, proteins, or small molecules. Some stabilizers may interact with cellular redox systems differently—e.g., a protein-capped SeNP may have slower release and less ROS generation, whereas a bare SeNP might induce stronger ROS in cancer cells. 2. Particle size: Smaller SeNPs (<50 nm) tend to generate more ROS and may enhance anticancer activity, but could theoretically interfere with ROS-dependent chemo if administered simultaneously. Larger SeNPs are slower-acting and may be safer alongside chemo. 3. Surface charge / coating: Positively charged or functionalized SeNPs can preferentially enter tumor cells, whereas neutral or negatively charged forms may distribute more evenly. This affects both selective cytotoxicity and interaction with normal cells. "30 mg of Na2SeO3.5H2O was added to 90 mL of Milli-Q water. Ascorbic acid (10 mL, 56.7 mM) was added dropwise to sodium selenite solution with vigorous stirring. 10 µL of polysorbate were added after each 2 ml of ascorbic acid. Selenium nanoparticles were formed after the addition of ascorbic acid. This can be visualized by a color change of the reactant solution from clear white to clear red. All solutions were made in a sterile environment by using a sterile cabinet and double distilled water." SeNPs Cancer relevant pathways
Selenium Nanoparticles (SeNPs) and Alzheimer’s Disease (AD)Overview: Selenium nanoparticles (SeNPs) are being investigated in Alzheimer’s disease primarily as a multifunctional neuroprotective nanoplatform rather than as a conventional nutrient supplement. In AD-oriented studies, SeNPs are used for one or more of the following: (1) direct inhibition of amyloid-β (Aβ) aggregation, (2) reduction of oxidative stress, (3) lowering of neuroinflammation, (4) improved blood-brain barrier (BBB) transport via targeting ligands, and/or (5) delivery or stabilization of partner compounds with poor brain availability. Current support is mainly from cell studies and rodent AD models, so the evidence is still experimental/preclinical, not established clinical therapy.
Mechanistic Summary
Overall Modulation Direction in AD
Evidence LevelPreclinical. The AD literature for SeNPs is mainly cell culture and rodent-model work. Formulation-specific effects are important; benefits shown for one coated or ligand-targeted SeNP system should not automatically be generalized to all selenium nanoparticles or to ordinary selenium supplementation. Notes / Interpretation
SeNP-Associated Products / Components Used in AD-Oriented Nanoformulations
Bottom LineFor AD, selenium nanoparticles appear most relevant as a multi-target anti-amyloid / antioxidant nanocarrier platform. Their strongest support is for reducing Aβ aggregation and oxidative-neuroinflammatory injury while improving delivery of partner neuroprotective compounds. At present, this is a research-stage strategy, not a validated clinical AD treatment. |
| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chlorogenic acid (CGA) is a polyphenol compound found in various plant-based foods, such as green coffee beans, apples, and pears. Chlorogenic acid (CGA; 5-caffeoylquinic acid) is a dietary polyphenol (coffee/tea/plant ester) whose primary biology in mammals is redox + stress-response modulation: (1) ROS scavenging/antioxidant buffering, (2) Keap1→NRF2 activation with induction of cytoprotective genes, and (3) downstream anti-inflammatory and survival/metabolic signaling changes (e.g., NF-κB, PI3K/Akt/mTOR/AMPK context-dependent). Oral exposure is PK-limited: after coffee doses, median peak plasma concentrations of CGA-related metabolites are ~1–1.5 µM (1088–1526 nM) , while many in-vitro cancer papers use 10–100+ µM, often exceeding realistic systemic exposure; effects can still be relevant in gut/liver (first-pass) but systemic tumor exposures are likely lower. Clinically, CGA has human PK evidence and extensive preclinical oncology; robust RCT-grade anticancer efficacy is not established, and NRF2 activation creates a credible radio/chemo-resistance risk in some contexts May lower blood pressure, blood sugar, and weight. May improve mood and cognitive function. Chlorogenic acid (CGA), one of the most abundant polyphenols in the human diet, has been reported to inhibit cancer cell growth. • Inhibiting the growth of cancer cells: CGA has been shown to inhibit the growth of cancer cells in vitro and in vivo, including breast, colon, and prostate cancer cells. • Inducing apoptosis: CGA has been found to induce apoptosis (cell death) in cancer cells, which can help prevent the spread of cancer. • Reducing inflammation: CGA has anti-inflammatory properties, which can help reduce the risk of cancer by reducing chronic inflammation. • Antioxidant activity: CGA has antioxidant properties, which can help protect cells from damage caused by free radicals. -vast array of sources, present in honeysuckle, potato, cork, eucommia leaves, chrysanthemum, strawberry, mango, blueberries, mulberry leaves, and green coffee Chlorogenic acid — Chlorogenic acid (CGA) is a dietary hydroxycinnamate polyphenol, classically the caffeoyl ester of quinic acid, with 5-O-caffeoylquinic acid as the major canonical form usually meant by “chlorogenic acid.” It is best classified as a small-molecule natural product/polyphenolic phytochemical rather than an approved anticancer drug. Standard abbreviations include CGA and, in chemistry-focused literature, 5-CQA or 5-O-caffeoylquinic acid. Major natural sources include coffee beans, certain fruits, vegetables, and medicinal plants. In oncology, CGA is best viewed as a context-dependent redox, inflammatory, metabolic, and immune-modulatory scaffold with strong preclinical activity but important translation limits because oral systemic exposure is modest and many cell-culture studies use concentrations above likely plasma-achievable levels. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral CGA is moderately absorbed and extensively metabolized, not absent from circulation. However, systemic exposure is dominated by conjugated and gut-derived metabolites, while exposure to intact parent CGA is relatively limited and variable. For pharmacology, this means dietary CGA can be biologically relevant, but many in-vitro studies still use concentrations above typical circulating parent-compound levels after ordinary oral intake. In-vitro vs systemic exposure relevance: This is a major translation constraint. Many oncology papers use roughly 10–200 µM or higher, while realistic oral systemic parent-CGA exposure is usually much lower; therefore many direct cytotoxic, anti-stemness, or signaling claims are likely more relevant to gut/liver first-pass settings, local delivery concepts, metabolite biology, or formulated/injectable products than to ordinary dietary exposure. Clinical evidence status: Extensive preclinical evidence; limited small-human oncology evidence. Early-phase clinical development exists for injectable CGA in recurrent high-grade glioma/advanced lung cancer programs, but robust randomized evidence for standard anticancer use is not established. Current evidence supports CGA mainly as a preclinical or adjunctive candidate, not a validated standalone cancer therapy. Plant Source CGA(mg/kg in dw) Instant coffee 2650–11,600 Mate tea 4800–24,900 Sunflower seeds 630–970 Sweet potato leaves 9600 English potato 1 3.3–9 Okra 1 3.9–21.6 Eggplant 4980–8050 Carrot 300–18,800 Tomato 200–400 Chlorogenic Acid Mechanistic Table
TSF Legend: P: 0–30 min (primary/rapid effects) R: 30 min–3 hr (acute signaling/stress) G: >3 hr (gene-regulatory adaptation)
Alzheimer’s disease contextChlorogenic acid — In the Alzheimer’s disease context, chlorogenic acid (CGA) is best classified as a multifunctional dietary polyphenol/neuroprotective small molecule with preclinical cholinergic, antioxidant, anti-inflammatory, and anti-amyloid activity rather than an established AD drug. Its AD relevance is supported by in vitro and animal-model evidence showing reduced acetylcholinesterase activity, lower oxidative stress, lower neuroinflammation, and improved cognitive performance in several paradigms. Standard abbreviations include CGA and 5-CQA. The strongest current interpretation is that CGA is a plausible adjunctive neuroprotective candidate with limited human cognitive-support data, but not a clinically validated treatment for Alzheimer’s disease. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral chlorogenic acids are meaningfully absorbed but extensively metabolized; circulating exposure includes parent compound plus conjugated and gut-derived phenolic metabolites. Brain penetration has been demonstrated in animal PK work, but CNS exposure is still constrained relative to many in vitro concentrations. In-vitro vs systemic exposure relevance: Many neuroprotection studies use pharmacologic concentrations or dosing paradigms not directly comparable to ordinary dietary intake. AD relevance is therefore biologically plausible but still translationally constrained by metabolism, CNS exposure, and model dependence. Clinical evidence status: Strong preclinical support; limited human cognitive-support evidence; no convincing clinical evidence that CGA is an established Alzheimer’s disease therapy. Chlorogenic Acid in Alzheimer’s Disease
TSF Legend: P: 0–30 min R: 30 min–3 hr G: >3 hr
|
| 6043- | CGA, | SeNPs, | Enhanced Effect of Combining Chlorogenic Acid on Selenium Nanoparticles in Inhibiting Amyloid β Aggregation and Reactive Oxygen Species Formation In Vitro |
| - | in-vitro, | AD, | NA |
| 6045- | CGA, | SeNPs, | A Flower-like Brain Targeted Selenium Nanocluster Lowers the Chlorogenic Acid Dose for Ameliorating Cognitive Impairment in APP/PS1 Mice |
| - | in-vivo, | AD, | NA |
| 6044- | SeNPs, | Chit, | CGA, | Ability of selenium species to inhibit metal-induced Aβ aggregation involved in the development of Alzheimer's disease |
| - | Study, | AD, | NA |
| 6046- | SeNPs, | CGA, | Anti-amyloidogenic properties of 5‑caffeoylquinic acid-capped selenium nanoparticles |
| - | Study, | AD, | NA |
| - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:391 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid